Expertise in
14
conditions

Dr. Dr Mary

Transplant Surgery
Office
675 N Saint Clair St Ste 100, 
Chicago, IL 
28 Years of Experience
Expertise in
14
conditions
Office
675 N Saint Clair St Ste 100, 
Chicago, IL 

Overview

Dr Mary is a Transplant Surgeon in Chicago, Illinois. Dr. Mary has been practicing medicine for over 28 years is highly rated in 14 conditions, according to our data. Her top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Cirrhosis, Liver Transplant, and Endoscopy.

Her clinical research consists of co-authoring 176 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Transplant Surgery

Licenses

Internal Medicine in IL

Hospital Affiliations

Northwestern Memorial Hospital
The University Of Chicago Medical Center
Adventist Hinsdale Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 13 Less Insurance Carriers -

Locations

Office
675 N Saint Clair St Ste 100, Chicago, IL 60611
Other Locations
Digestive Health Center
259 E Erie St Fl 16, Chicago, IL 60611

Additional Areas of Focus

Dr. Mary has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Device
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
Enrollment Status: Completed
Publish Date: May 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

176 Total Publications

MASLD as a complication of obesity must include liver risk stratification.
MASLD as a complication of obesity must include liver risk stratification.
Journal: Nature medicine
Published: January 07, 2026
Similar Doctors
Daniel R. Ganger
Expertise in
14
conditions
Dr. Daniel R. Ganger
Transplant Surgery
Expertise in
14
conditions
Dr. Daniel R. Ganger
Transplant Surgery
259 E Erie St Ste 1600, Lavin Family Pavilion, 
Chicago, IL 
 (7.4 miles away)
312-695-4837
Experience:
49+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Ganger is a Transplant Surgeon in Chicago, Illinois. Dr. Ganger has been practicing medicine for over 49 years is highly rated in 14 conditions, according to our data. His top areas of expertise are Liver Failure, Hepatitis, Cirrhosis, Liver Transplant, and Endoscopy.

Expertise in
15
conditions
Dr. Daniela P. Ladner
Transplant Surgery
Expertise in
15
conditions
Dr. Daniela P. Ladner
Transplant Surgery
676 N St Clair St 19th Fl, Arkes Pavilion, 
Chicago, IL 
 (7.4 miles away)
312-695-8900
Experience:
30+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniela Ladner is a Transplant Surgeon in Chicago, Illinois. Dr. Ladner has been practicing medicine for over 30 years is highly rated in 15 conditions, according to our data. Her top areas of expertise are Liver Failure, Hepatitis, Polycystic Kidney Disease, Liver Transplant, and Kidney Transplant.

Expertise in
9
conditions
Dr. Dr Piotr
Transplant Surgery
Expertise in
9
conditions
Dr. Dr Piotr
Transplant Surgery

University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (0.1 miles away)
773-702-4500
Languages Spoken:
English
See accepted insurances

Dr Piotr is a Transplant Surgeon in Chicago, Illinois. Dr. Piotr is highly rated in 9 conditions, according to our data. His top areas of expertise are Chronic Pancreatitis, Hereditary Pancreatitis, Childhood Pancreatitis, Islet Cell Transplantation, and Pancreatectomy.

Frequently Asked Questions about Dr. Dr Mary

How do I make an appointment with Dr. Dr Mary?

You can book an appointment with Dr. Dr Mary by calling their office at 312-926-4525. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dr Mary a top-rated expert for Nonalcoholic Steatohepatitis (NASH)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dr Mary is classified as an Elite expert for Nonalcoholic Steatohepatitis (NASH), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dr Mary specialize in?

While Dr. Dr Mary is a Transplant Surgery, they have specific expertise in Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Transplant Surgery.

Does Dr. Dr Mary participate in research or clinical trials?

Yes. Dr. Dr Mary has published 176 articles and abstracts on conditions like Nonalcoholic Steatohepatitis (NASH). You can view a list of Dr. Dr Mary's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dr Mary accept my insurance?

Dr. Dr Mary accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 312-926-4525 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mary's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile